ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

NVX-CoV2373 adjuvated lipid nanoparticle

Also written as “NVX-CoV2373”, “SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)” and “NVX-Cov2373”.

Its studies are mostly in COVID-19 · Severe Acute Respiratory Syndrome, led by 4 companies.

Drug pageNVX-CoV2373 adjuvated lipid nanoparticle: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 4, 202416 company-led studies, 1 open or runningNext primary completion: Nov 26, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novavaxits history only120 open or runningphase 4since Oct 4, 2024Apr 24, 2020none ahead
Takedaits history only20 open or runningphase 3since Mar 27, 2022Jan 14, 2021none ahead
Cogna Technology Solutions10 open or runningphase 3since Feb 18, 2022Feb 18, 2022none ahead
Sanofiits history only11 open or runningphase 4since Sep 30, 2026Sep 30, 2026Nov 26, 2026phase 4 · NCT07861542

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cogna Technology Solutions only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 18, 2022First study: phase 3 study in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)First studyNCT05249816 · 1,000 enrolled · United Arab Emirates

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

The one study Cogna Technology Solutions leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05249816Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) · United Arab Emirates3CompletedMay 4, 20231,000

How it is read

Names in the registry

  • “NVX-CoV2373”, 3 entries
  • “SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)”, 2 entries
  • “NVX-Cov2373”, 2 entries
  • “TAK-019”, 2 entries
  • “Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.